{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T23:07:34Z","timestamp":1778972854594,"version":"3.51.4"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ejmech.2020.112687","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T02:27:02Z","timestamp":1595903222000},"page":"112687","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Potential treatment methods targeting 2019-nCoV infection"],"prefix":"10.1016","volume":"205","author":[{"given":"Lu","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiamin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kutty Selva","family":"Nandakumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kui","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejmech.2020.112687_bib1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3390\/jcm9020575","article-title":"Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China","volume":"9","author":"Deng","year":"2020","journal-title":"J.\u00a0Clin. Med."},{"issue":"18","key":"10.1016\/j.ejmech.2020.112687_bib2","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2020.112687_bib3","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.cca.2020.06.032","article-title":"Impact of heat-inactivation on the detection of SARS-CoV-2 IgM and IgG antibody by ELISA [published online ahead of print, 2020 Jun 20]","volume":"509","author":"Hu","year":"2020","journal-title":"Clin. Chim. Acta"},{"issue":"7","key":"10.1016\/j.ejmech.2020.112687_bib4","doi-asserted-by":"crossref","first-page":"450","DOI":"10.21037\/atm.2020.03.132","article-title":"Deep learning for detecting corona virus disease 2019 (COVID-19) on high-resolution computed tomography: a pilot study","volume":"8","author":"Yang","year":"2020","journal-title":"Ann. Transl. Med."},{"issue":"6","key":"10.1016\/j.ejmech.2020.112687_bib5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jmv.25726","article-title":"Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2","volume":"92","author":"Liu","year":"2020","journal-title":"J.\u00a0Med. Virol."},{"issue":"1","key":"10.1016\/j.ejmech.2020.112687_bib6","first-page":"3","article-title":"Properties of coronavirus and SARS-CoV-2","volume":"42","author":"Malik","year":"2020","journal-title":"Malays. J. Pathol."},{"issue":"2","key":"10.1016\/j.ejmech.2020.112687_bib7","doi-asserted-by":"crossref","first-page":"271-280","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.ejmech.2020.112687_bib8","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2165\/00003495-200363080-00004","article-title":"Lopinavir\/ritonavir: a review of its use in the management of HIV infection","volume":"63","author":"Cvetkovic","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2020.112687_bib9","doi-asserted-by":"crossref","first-page":"104786","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in\u00a0vitro [published online ahead of print, 2020 Apr 3]","volume":"178","author":"Choy","year":"2020","journal-title":"Antivir. Res."},{"issue":"6","key":"10.1016\/j.ejmech.2020.112687_bib10","first-page":"3390","article-title":"Clinical efficacy of lopinavir\/ritonavir in the treatment of Coronavirus disease 2019","volume":"24","author":"Ye","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2020.112687_bib11","article-title":"A\u00a0trial of lopinavir-ritonavir in adults hospitalized with severe covid-19 [published online ahead of print, 2020 mar 18]","author":"Cao","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ejmech.2020.112687_bib12","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/jac\/dkv018","article-title":"Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases","volume":"70","author":"Al-Bari","year":"2015","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2020.112687_bib13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol. J."},{"issue":"3","key":"10.1016\/j.ejmech.2020.112687_bib14","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in\u00a0vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2020.112687_bib15","doi-asserted-by":"crossref","first-page":"105945","DOI":"10.1016\/j.ijantimicag.2020.105945","article-title":"Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine [published online ahead of print, 2020 Mar 17]","author":"Sahraei","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2020.112687_bib16","article-title":"In\u00a0vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [published online ahead of print, 2020 mar 9]","author":"Yao","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.112687_bib17","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial [published online ahead of print, 2020 Mar 20]","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"7","key":"10.1016\/j.ejmech.2020.112687_bib18","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41419-020-2721-8","article-title":"Is hydroxychloroquine beneficial for COVID-19 patients?","volume":"11","author":"Li","year":"2020","journal-title":"Cell Death Dis."},{"issue":"25","key":"10.1016\/j.ejmech.2020.112687_bib19","doi-asserted-by":"crossref","first-page":"8544","DOI":"10.1021\/jp102619w","article-title":"Membranotropic effects of arbidol, a broad anti-viral molecule, on phospholipid model membranes","volume":"114","author":"Villala\u00edn","year":"2010","journal-title":"J.\u00a0Phys. Chem. B"},{"key":"10.1016\/j.ejmech.2020.112687_bib20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","article-title":"Arbidol as a broad-spectrum antiviral: an update","volume":"107","author":"Blaising","year":"2014","journal-title":"Antivir. Res."},{"issue":"4","key":"10.1016\/j.ejmech.2020.112687_bib21","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/v10040184","article-title":"Arbidol (umifenovir): a broad-spectrum antiviral drug that inhibits medically important arthropod-borne flaviviruses","volume":"10","author":"Haviernik","year":"2018","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.ejmech.2020.112687_bib22","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1128\/JVI.02077-15","article-title":"The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses","volume":"90","author":"P\u00e9cheur","year":"2016","journal-title":"J.\u00a0Virol."},{"issue":"28","key":"10.1016\/j.ejmech.2020.112687_bib23","article-title":"The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in\u00a0vitro","volume":"6","author":"Wang","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.ejmech.2020.112687_bib24","article-title":"Arbidol monotherapy is superior to lopinavir\/ritonavir in treating COVID-19 [published online ahead of print, 2020 Apr 10]","author":"Zhu","year":"2020","journal-title":"J.\u00a0Infect."},{"issue":"20","key":"10.1016\/j.ejmech.2020.112687_bib25","first-page":"30113","article-title":"Arbidol combined with LPV\/r versus LPV\/r alone against Corona Virus Disease 2019: a retrospective cohort study [published online ahead of print, 2020 Mar 11]","author":"Deng","year":"2020","journal-title":"J.\u00a0Infect."},{"key":"10.1016\/j.ejmech.2020.112687_bib26","doi-asserted-by":"crossref","first-page":"101647","DOI":"10.1016\/j.tmaid.2020.101647","article-title":"Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: an evaluation of the evidence","volume":"35","author":"Cao","year":"2020","journal-title":"Trav. Med. Infect. Dis."},{"issue":"2","key":"10.1016\/j.ejmech.2020.112687_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.ejmech.2020.112687_bib28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","article-title":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model","volume":"105","author":"Oestereich","year":"2014","journal-title":"Antivir. Res."},{"issue":"7","key":"10.1016\/j.ejmech.2020.112687_bib29","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.ejmech.2020.112687_bib30","series-title":"Experimental Treatment with Favipiravir for COVID-19: an Open-Label Control Study [published Online Ahead of Print, 2020 Mar 18]","author":"Cai","year":"2020"},{"issue":"7","key":"10.1016\/j.ejmech.2020.112687_bib31","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.3390\/ijms21072657","article-title":"A\u00a0review of SARS-CoV-2 and the ongoing clinical trials","volume":"21","author":"Tu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2020.112687_bib32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/liv.13212","article-title":"Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection","volume":"37","author":"Feld","year":"2017","journal-title":"Liver Int."},{"issue":"10223","key":"10.1016\/j.ejmech.2020.112687_bib33","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ejmech.2020.112687_bib34","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/14656566.2018.1484901","article-title":"Darunavir for the treatment of HIV infection","volume":"19","author":"Spagnuolo","year":"2018","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2020.112687_bib35","article-title":"The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China [published online ahead of print, 2020 Mar 20]","author":"Ding","year":"2020","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.ejmech.2020.112687_bib36","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1017\/erm.2018.3","article-title":"What has traditional Chinese medicine delivered for modern medicine?","volume":"20","author":"Wang","year":"2018","journal-title":"Expet Rev. Mol. Med."},{"key":"10.1016\/j.ejmech.2020.112687_bib37","first-page":"CD004882","article-title":"Chinese herbs combined with Western medicine for severe acute respiratory syndrome (SARS)","volume":"1","author":"Liu","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2020.112687_bib38","doi-asserted-by":"crossref","first-page":"104743","DOI":"10.1016\/j.phrs.2020.104743","article-title":"Traditional Chinese medicine for COVID-19 treatment [published correction appears in Pharmacol Res. 2020 Mar 25;:104768]","volume":"155","author":"Ren","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2020.112687_bib39","doi-asserted-by":"crossref","first-page":"104761","DOI":"10.1016\/j.phrs.2020.104761","article-title":"Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)","volume":"156","author":"Li","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2020.112687_bib40","article-title":"Retrospective clinical analysis on treatment of novel coronavirus-infected pneumonia with traditional Chinese medicine lianhua qingwen","author":"Yao","year":"2020","journal-title":"Chin. J. Exp. Tradit. Med. Form."},{"issue":"2","key":"10.1016\/j.ejmech.2020.112687_bib41","first-page":"152","article-title":"Convalescent plasma: new evidence for an old therapeutic tool?","volume":"14","author":"Marano","year":"2016","journal-title":"Blood Transfus."},{"key":"10.1016\/j.ejmech.2020.112687_bib42","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"27","author":"Shen","year":"2020","journal-title":"J.\u00a0Am. Med. Assoc."},{"key":"10.1016\/j.ejmech.2020.112687_bib43","article-title":"Convalescent plasma transfusion for the treatment of COVID-19: systematic review [published online ahead of print, 2020 May 1]","author":"Rajendran","year":"2020","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.ejmech.2020.112687_bib44","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cytogfr.2020.05.002","article-title":"COVID-19: pathogenesis, cytokine storm and therapeutic potential of interferons","volume":"53","author":"Nile","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"issue":"12","key":"10.1016\/j.ejmech.2020.112687_bib45","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/s41590-019-0466-2","article-title":"Interferon target-gene expression and epigenomic signatures in health and disease","volume":"20","author":"Barrat","year":"2019","journal-title":"Nat. Immunol."},{"issue":"11","key":"10.1016\/j.ejmech.2020.112687_bib46","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028423","article-title":"The interferon (IFN) class of cytokines and the IFN regulatory factor (IRF) transcription factor family","volume":"10","author":"Negishi","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.ejmech.2020.112687_bib47","doi-asserted-by":"crossref","first-page":"101300","DOI":"10.1016\/j.smim.2019.101300","article-title":"Global virus outbreaks: interferons as 1st responders","volume":"43","author":"Wang","year":"2019","journal-title":"Semin. Immunol."},{"issue":"2","key":"10.1016\/j.ejmech.2020.112687_bib48","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ijgo.13146","article-title":"Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection","volume":"149","author":"Chen","year":"2020","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"2","key":"10.1016\/j.ejmech.2020.112687_bib49","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cvsm.2017.10.002","article-title":"Recent advances in vaccine technologies","volume":"48","author":"Francis","year":"2018","journal-title":"Vet. Clin. North Am. Small Anim. Pract."},{"issue":"3","key":"10.1016\/j.ejmech.2020.112687_bib50","doi-asserted-by":"crossref","first-page":"E623","DOI":"10.3390\/jcm9030623","article-title":"Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic review","volume":"9","author":"Pang","year":"2020","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.ejmech.2020.112687_bib51","author":"Folegatti","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.112687_bib52","article-title":"Structure of Mpro from COVID-19 virus and discovery of its inhibitors [published online ahead of print, 2020 Apr 9]","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2020.112687_bib53","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease [published online ahead of print, 2020 Apr 22]","author":"Dai","year":"2020","journal-title":"Science"},{"issue":"6489","key":"10.1016\/j.ejmech.2020.112687_bib54","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u00e1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.ejmech.2020.112687_bib55","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cell Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420306590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420306590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:12:21Z","timestamp":1759327941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420306590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":55,"alternative-id":["S0223523420306590"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112687","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential treatment methods targeting 2019-nCoV infection","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112687","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112687"}}